Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Phase 1

Recruiting

Conditions: Myeloid Leukemia, Philadelphia Positive

Interventions: Drug: Asciminib Pediatric formulation group
Drug: Asciminib Adult formulation group

First Posted Date: 2021-06-14

Last Posted Date: 2024-11-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT04925479

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
Columbia University Medical Center New York Presbyterian, New York, New York, United States

and more 4 locations

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

Interventions: Drug: VAY736
Drug: lenalidomide

First Posted Date: 2021-05-26

Last Posted Date: 2024-11-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT04903197

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore

Global Managed Access Program Cohort for Ligelizumab in CSU

Conditions: Chronic Spontaneous Urticaria

First Posted Date: 2021-05-26

Last Posted Date: 2022-05-11

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04903613

Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant
Drug: Metformin XR
Drug: Dapagliflozin + metformin XR
Drug: Dapagliflozin

First Posted Date: 2021-05-24

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2

Registration Number: NCT04899349

Locations: 🇺🇸
Washington Uni School of Med Siteman Cancer Center, Saint Louis, Missouri, United States
🇲🇾
Novartis Investigative Site, Kuala Lumpur, Malaysia

Study of Safety, Tolerability, and Pharmacokinetics of INE963 in Healthy Participants

Phase 1

Terminated

Conditions: Healthy Volunteers

Interventions: Drug: INE 963
Other: Placebo

First Posted Date: 2021-05-21

Last Posted Date: 2023-09-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT04896632

Locations: 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom

DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies

Phase 1

Active, not recruiting

Conditions: Carcinoma, Renal Cell

Interventions: Drug: DFF332
Drug: RAD001
Drug: PDR001
Drug: NIR178

First Posted Date: 2021-05-20

Last Posted Date: 2024-11-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT04895748

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸
Memorial Sloane Ketterin Cancer Ctr, New York, New York, United States

and more 3 locations

A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China

Completed

Conditions: Psoriasis

Interventions: Drug: secukinumab

First Posted Date: 2021-05-20

Last Posted Date: 2024-03-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1002

Registration Number: NCT04894890

Locations: 🇨🇳
Novartis Investigative Site, Zhejiang, China

Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

Terminated

Conditions: Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity

Interventions: Other: Siponimod

First Posted Date: 2021-05-20

Last Posted Date: 2023-08-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT04895202

Locations: 🇨🇭
Novartis Investigative Site, Winterthur, Switzerland

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Phase 3

Recruiting

Conditions: Atypical Hemolytic Uremic Syndrome

Interventions: Drug: Iptacopan

First Posted Date: 2021-05-17

Last Posted Date: 2024-12-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 50

Registration Number: NCT04889430

Locations: 🇺🇸
Uni Of Alabama At Birmingham, Birmingham, Alabama, United States
🇺🇸
Univ of California at Los Angeles, Los Angeles, California, United States
🇺🇸
Univ Cali Irvine ALS Neuromuscular, Orange, California, United States

and more 18 locations

Study of Efficacy, Safety and Tolerability of DFV890 in Patients With Knee Osteoarthritis

Phase 2

Active, not recruiting

Conditions: Symptomatic Knee Osteoarthritis

Interventions: Drug: Placebo
Drug: DFV890

First Posted Date: 2021-05-14

Last Posted Date: 2024-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 115

Registration Number: NCT04886258

Locations: 🇺🇸
TriWest Reserach Associates ., El Cajon, California, United States
🇺🇸
ARENSIA Explor Med Res Clinic Research, Phoenix, Arizona, United States
🇺🇸
Horizon Clinical Research, La Mesa, California, United States

and more 7 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy